P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS - Deyan Yosifov; Julia von Tresckow; Adam Giza; Sandra Robrecht; Christof Schneider; Billy Jebaraj; Daniel Mertens; Matthias Ritgen; Anke Schilhabel; Karl-Anton Kreuzer; Anna Maria Fink; Othman Al-Sawaf; et al. (HemaSphere, 2023)